Chloroquine News and Research

RSS

Restanza shows greater efficacy against species of Plasmodium that cause malaria

Advanced Life Sciences Holdings, Inc., a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic areas of infection, oncology and respiratory diseases, today announced positive results from in vitro and in vivo studies assessing the efficacy of Restanza (cethromycin), its novel oral antibiotic, against the species of Plasmodium that cause malaria.

27 May 2010

Live malaria parasites in the skin shut down immune responses and block vaccine function: Study

Why one after another new malaria vaccine tests well in the laboratory but fails in field trials has frustrated legions of malaria researchers, and has been the main stumbling block to malaria eradication. Now, a research team from Germany has unraveled that puzzle and shown that the problem is all about the skin and how it controls the immune system. The implications are profound.

20 May 2010

Tulane University researchers urge action to eliminate malaria from Hispaniola

In an editorial in the May 2010 issue of the journal The Lancet Infectious Diseases, Tulane University malaria researchers urge action to eliminate malaria from Hispaniola, the last island in the Caribbean where the disease occurs regularly.

29 Apr 2010

MMV supports Pfizer's AZCQ clinical trial for intermittent preventive treatment of malaria in pregnant women

Pfizer Inc. and Medicines for Malaria Venture (MMV) entered into an agreement for the development, access and delivery of a fixed-dose combination treatment consisting of azithromycin dihydrate (AZ) and chloroquine phosphate (CQ) for the Intermittent Preventive Treatment of P. falciparum malaria in pregnancy (IPTp). There is currently an unmet need for new treatment options and the World Health Organization (WHO) estimates that some 30 million pregnant women are at risk for malaria in endemic areas in Africa each year.

23 Apr 2010

PINC trial to test anti-malarial drug in women with DCIS

Can a drug that has been used to treat malaria for years possibly be used to treat breast cancer before it becomes invasive? That's what researchers at George Mason University's Center for Applied Proteomics and Molecular Medicine (CAPMM) and Inova Breast Care Institute (IBCI) are trying to prove.

3 Mar 2010

Researchers discover chemical compound to combat malaria and bacterial diseases

Researchers report that they have discovered - and now know how to exploit - an unusual chemical reaction mechanism that allows malaria parasites and many disease-causing bacteria to survive. The research team, from the University of Illinois, also has developed the first potent inhibitor of this chemical reaction.

16 Feb 2010

Antimalarial medicines in African countries are substandard, says QAMSA study

The first results from a large-scale study of key antimalarial medicines in ten Sub-Saharan African countries reveal that a high percentage of medicines circulating on national markets are of substandard quality and thus may contribute to the growth of drug-resistant strains of Plasmodium falciparum, the most virulent form of malaria.

10 Feb 2010

Johns Hopkins scientists find a source of nonallergic itch

Scratching below the surface of a troublesome sensation that's equal parts tingle-tickle-prickle, sensory scientists from Johns Hopkins have discovered in mice a molecular basis for nonallergic itch.

23 Dec 2009

HDAC inhibitors: New therapy for treating breast cancer

A powerful new breast cancer treatment could result from packaging one of the newer drugs that inhibits cancer's hallmark wild growth with another that blocks a primordial survival technique in which the cancer cell eats part of itself, researchers say.

17 Nov 2009

Opinions: Obstetric fistula; malaria and climate change

In a New York Times opinion piece, columnist Nicholas Kristof examines a new plan to tackle obstetric fistula, "a childbirth injury, often suffered by a teenager in Africa or Asia whose pelvis is not fully grown." According to Kristof, "Just about the happiest thing that can happen to such a woman is an encounter with Dr. Lewis Wall, an ob-gyn at Washington University in St. Louis.

3 Nov 2009

ACTwatch data indicates low accessibility of artemisinin combination therapy

ACTwatch, a research project led by PSI, in collaboration with the London School of Hygiene and Tropical Medicine, released evidence today that indicates that artemisinin combination therapy, the most effective medicines for treating malaria, continue to have a significantly low presence on the market among populations considered to be most at risk.

2 Nov 2009

Research on malarial drugs for travelers

A new review of existing research finds that a combination drug and the common antibiotic doxycycline allow travelers to fend off malaria with the fewest side effects in areas where the parasite is resistant to a widely accepted preventive treatment.

7 Oct 2009

Also in Global Health news: News outlets explore AIDS vaccine research; chloroquine resistance unraveled; authorities contest maternal mortality report

The Associated Press examines the role of the Thai participants in the recent clinical trial of an experimental HIV vaccine which showed modest potential for preventing infection. "Nearly 16,000 Thais ignored the false rumors that they were being infected by the AIDS virus, and overcame their fears of becoming social outcasts to participate in trials of the first vaccine found to prevent infection with the deadly virus," the news service writes (Ahuja/Casey, 9/27).

29 Sep 2009

Study in Asia finds monkey malaria strain more widespread in humans than previously thought

"Researchers in Malaysia have confirmed that a form of malaria thought to primarily affect monkeys can infect and kill humans, according to a study published in Clinical Infectious Diseases journal," Agence France-Presse reports.

11 Sep 2009

New form of malarial infection identified

Researchers in Malaysia have identified key laboratory and clinical features of an emerging new form of malaria infection. The research, funded by the Wellcome Trust, confirms the potentially deadly nature of the disease.

10 Sep 2009

Malaria: Artemisinin resistance continues developing in western Cambodia

Artemisinin, the "basis of the most effective" malaria treatment recommended by the WHO, took nearly twice as long to clear malaria parasites in patients in western Cambodia than it did in patients in northwestern Thailand, according to a New England Journal of Medicine study, which shows the "drugs are losing their power against the disease in Cambodia," Bloomberg reports (Bennett, 7/30).

30 Jul 2009

Therapeutic effect of imatinib improved with addition of chloroquine

The therapeutic effects of the blockbuster leukemia drug imatinib may be enhanced when given along with a drug that inhibits a cell process called autophagy, researchers from the Kimmel Cancer Center at Jefferson reported in the Journal of Clinical Investigation.

13 Apr 2009

Discovery of variations in resistance to sulfadoxine across Africa

Researchers have discovered that malaria parasites in east and west Africa carry different resistance mutations, which suggests that the effectiveness of sulfadoxine as an antimalarial drug may vary across Africa.

13 Apr 2009

Coartem tablets approved in U.S. to treat malaria

The U.S. Food and Drug Administration has approved Coartem tablets (artemether and lumefantrine) for the treatment of acute, uncomplicated malaria infections in adults and children weighing at least five kilograms (approximately 11 pounds).

8 Apr 2009

Hendra and Nipah viruses shown to be susceptible to chloroquine

Two highly lethal viruses that have emerged in recent outbreaks are susceptible to chloroquine, an established drug used to prevent and treat malaria, according to a new basic science study by researchers at Weill Cornell Medical College in the Journal of Virology.

5 Mar 2009